2006
DOI: 10.1111/j.1600-6143.2006.01381.x
|View full text |Cite
|
Sign up to set email alerts
|

Reverse Diastolic Intrarenal Flow Due to Calcineurin Inhibitor (CNI) Toxicity

Abstract: Renal calcineurin inhibitor (CNI) toxicity is a frequent side effect of immunosuppression with CNIs in solid organ transplantation, leading to acute and chronic renal failure. Acute CNI toxicity is due to vasoconstriction of the vasa afferens and efferens and vacuolization of smooth muscle cells with medial hyalinosis, leading to vessel lumen narrowing.Our case had an acute renal failure 8 months after deceased donor kidney transplantation under treatment with tacrolimus, sirolimus and prednisolone. In Doppler… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2008
2008
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(2 citation statements)
references
References 20 publications
0
2
0
Order By: Relevance
“…With the increasing use of different immunosuppressive combinations after transplantation, their influence on early graft function should be better characterized. Calcineurin inhibitor toxicity is well‐known to affect graft function through its renal vasoconstrictive effects (5).…”
mentioning
confidence: 99%
“…With the increasing use of different immunosuppressive combinations after transplantation, their influence on early graft function should be better characterized. Calcineurin inhibitor toxicity is well‐known to affect graft function through its renal vasoconstrictive effects (5).…”
mentioning
confidence: 99%
“…[10,11] Reversible histological changes have also been demonstrated including, on rare occasions, thrombotic microangiopathy. [12][13][14] CCBs such as nicardipine are commonly used to manage hypertension both before and after renal transplantation. Nicardipine inhibits the cytochrome P450 enzyme CYP3A4, which along with CYP3A5 is involved in the metabolic pathway for tacrolimus in the liver.…”
Section: Discussionmentioning
confidence: 99%